Brainsway Ltd. (TASE:BRIN) today reported positive interim results in the trial of the effectiveness of its Deep TMS (transcranial magnetic stimulation) device in helping COPD (Chronic Obstructive Pulmonary Disease) sufferers to quit smoking. TMS is being tested in treating a range of neurological disorders.
The trial involving 31 patients is being conducted at the Beer Yaakov Medical Center. The patients are divided into three groups receiving high frequency, low frequency and placebo treatment. Half of each group is also exposed to stimulation to desire to smoke.
Analysis of the interim results found that the group receiving high frequency TMS treatment reduced smoking by more than 50% in 60% of patients, compared with 20% in the other groups. In addition, in the group that received high frequency treatment and was exposed to stimulation of the desire to smoke there was 43% success in complete cessation of smoking compared with 0% in the low frequency group and 12.5% in the placebo group.
Brainsway's share price rose 2.2% to NIS 7.49 in afternoon trading on the TASE.
Published by Globes, Israel business news - www.globes-online.com - on November 30, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010